5Vote!
iStockAnalyst.com (Free subscription) | yesterday
As of today the top ten most traded option contracts were: Johnson & Johnson (JNJ) January 55 Call OptionsJohnson & Johnson January 50 Call OptionsJohnson & Johnson November 60 Call OptionsS&P 500 SPDR (SPY) November 110 Call OptionsS&P 500 SPDR November 109 Put OptionsPowerShares QQQ (QQQQ) November 43 Put OptionsS&P 500 SPDR November 110 Put OptionsS&P 500 SPDR November...
4Vote!
MarketIntelligenceCenter.com (Free subscription) | 11/18/2009
Sara Lee (NYSE: SLE) hit a new 52-Week high of $12.31 so far today, helped by reports that the company may sell its air-freshner business to S.C. Johnson. Currently the stock is up $0.11 (0.9%) to $12.31 on 2,945,113 shares traded. Today's high is up $5.51 from a 52-Week Low of $6.80. Sara Lee stock has been showing support around $11.83 and resistan...
5Vote!
Dividend Growth Investor (Free subscription) | 11/18/2009
Great investors have goals and strategies are only the tools that help them accomplish their targets. My goal is to generate a rising stream of dividend income, which would allow me to leave the rat race and spend my time doing worthwhile things like education and charity and self-development. By focusing on dividend growth , I am trying to pick the stocks, which have solid competitive advantages,...
5Vote!
Business Wire (Free subscription) | 11/16/2009
GLENVIEW, Ill.--(BUSINESS WIRE)--Mead Johnson Nutrition Company (NYSE: MJN) announced today that it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC), which includes details of a proposed exchange offer whereby Bristol-Myers Squibb Company (BMS) shareholders can exchange some, none or all of their shares of BMS common stock for shares of Mead Johnson...
4Vote!
Business Wire (Free subscription) | 11/16/2009
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver value to Bristol-Myers Squibb shareholders. The split-off is expected to be net cash flow positive to the BioPharma business and accretive to earnings per share beginning...
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 11/14/2009
( EMAILWIRE.COM , November 13, 2009 ) Del Mar, CA While livestock and their by-products account for a staggering 51% of annual worldwide greenhouse gas emissions, one of the more pressing issues faced globally, eco-friendly solutions are needed in order to protect our planet for future generations. Green Energy Live, a clean energy company on the rise, provides a Green resolution as it engages in the...
5Vote!
Madd Money (Free subscription) | 11/13/2009
For the “Off The Charts” segment, Cramer went up against his colleague at TheStreet.com Dan Fitzpatrick over the charts of health care stocks, Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ), the former which Cramer holds in his charitable trust. Fitzpatrick thinks that Abbott Labs is about to beak out to the upside, while Johnson [...]
11Vote!
Media Matters for America (Free subscription) | 11/12/2009
From Siegel's November 12 New York Post column , "The AMA's 'reform' sellout": The American Medical Association leadership is spineless when it comes to the health reforms now before Congress. The organization has focused almost entirely on a single issue -- the repeal of the Medicare Sustainable Growth Rate formula, which penalizes doctors a percentage every year if the total amount we're...
6Vote!
From On High (Free subscription) | 11/12/2009
Here in Southwest Virginia, on plats where weeds grow in abundance these days, Mack Truck, Ethan Allen, Celanese Acetate, Johnson & Johnson, Lear Corp., Dan River, Tultex, Spring Ford Industries, National Textiles, Buster Brown, Natalie Knitting Mills, American of Martinsville, Virginia Glove, Virginia House Furniture, Lea Industries, ArvinMeritor, Alcoa Wheels, Rowe Furniture, VF Knitwear, Vaughan...
3Vote!
10Q Detective (Free subscription) | 11/12/2009
Johnson & Johnson’s Invega (paliperidone) is no Dorothy Hamill poised to skate away with the gold anytime soon. The heralded successor to the schizophrenic drug Risperdal took a tumble after flubbing the double lutz. Third-quarter U.S. revenue fell 16.4 percent to $61 million, and Invega slowly wobbled away out of the rink – but not out of sight of prying eyes: providers voicing skepticism...
5Vote!
TAG Blog (Free subscription) | 11/12/2009
Over the last few years of the TAG Blog, I've dwelt occasionally on the subject of foreign levies , and the fact that the WGA and DGA distribute these European "royalties" (which are derived from taxes collected on behalf of writers and directors working in film and television) to scribes and directors in the U.S. of A. Ever since the WGA and DGA started distributing these monies, the DGA...
4Vote!
Business Wire (Free subscription) | 11/11/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boston Scientific Corporation (NYSE: BSX), Johnson & Johnson (NYSE: JNJ), Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT)...
3Vote!
Uremic Frost (Free subscription) | 11/11/2009
A study printed in the Journal of the National Cancer Institute has taken a look at cancer patients using erythrocyte stimulating agents (ESA)... and it is not good news for Johnson & Johnson and Amgen. The study examined patient with cancer, not CKD. They evaluated 56,210 patients who were diagnosed with lymphoma, breast cancer, non-small cell lung cancer, or colon cancer over a 10-year period...
4Vote!
StreetInsider.com News Articles (Free subscription) | 11/10/2009
StreetInsider.com Notable ETF Movers: HIGHER: iPath DJ AIG Platinum TR Sub-Idx ETN (NYSE: PGM) Up 6.10%, as platinum futures are down about 1.4%. Investors might be looking for exposure in a different metals other than gold and silver, as many commodities have been having a good year so far. Health Care Select Sector SPDR (NYSE: XLV) up about 0.50%. Major holdings include Johnson & Johnson (NYSE:...
1Vote!
high-tech | 06/16/2009
Biosurgery products development startup LifeBond has raised $8 million in a second financing round led by Pitango Venture Capital and Robert Taub , founder and former CEO of Omrix Biopharmaceuticals , which acquired by Johnson & Johnson for $438 million. Existing investors: GlenRock Israel , Leon Recanati’s investment company, and Zitelman Group , also participating in this round. LifeBond is developing